About Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics is a private company based in Doylestown, Pennsylvania. It has reported $875,000 raised in two offerings on Form D since October 2018. Its chief executive is David Horn.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Not yet | Sep 30, 2024 | $0of $5.0M target | 0 | — | Equity, OptionsRule 506(c) | Form D ↗ |
| Jun 28, 2018 | Oct 11, 2018 | $875,000of $10.0M target | 1 | $875K | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $875,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Mid-Atlantic BioTherapeutics's Form D filed Sep 30, 2024.
JC
Julian Chick
Director
DH
David Horn
Chief Executive Officer and director
MG
Michael Goldblatt
Director
AK
Andrew Katz
Director
DJ
David Jobes
President and director
JG
Jean Pierre Gagnon
Director